Aztreonam is NOT appropriate for treating CRAB infections
Aztreonam has no activity against Acinetobacter baumannii, including carbapenem-resistant strains (CRAB), and should never be used as monotherapy or in combination for these infections. 1, 2
Why Aztreonam Fails Against CRAB
Mechanism of Resistance
Aztreonam is a monobactam antibiotic with activity limited to aerobic gram-negative bacilli, but A. baumannii is intrinsically resistant to aztreonam 1, 3. Multiple studies confirm:
- In vitro testing shows aztreonam alone or combined with avibactam has no activity against A. baumannii isolates 2
- Resistance rates to aztreonam in CRAB exceed 98% 4
- The drug's mechanism of action (inhibition of penicillin-binding proteins) is ineffective against Acinetobacter's resistance mechanisms 1
Clinical Evidence Against Use
Research demonstrates aztreonam/ceftazidime/avibactam combinations achieve <2 log10 CFU/mL reduction by 24 hours against NDM-producing CRAB, indicating clinical futility 5. Even when combined with polymyxin B, the aztreonam component contributes no meaningful antibacterial effect 5.
Appropriate Treatment Options for CRAB
Guideline-Recommended Regimens
Based on the most recent ESCMID 2022 guidelines 6:
For sulbactam-susceptible CRAB with HAP/VAP:
- Use ampicillin-sulbactam (conditional recommendation)
For sulbactam-resistant CRAB:
- Polymyxin (if susceptible) OR
- High-dose tigecycline (if susceptible)
- Note: Cefiderocol is conditionally recommended AGAINST for CRAB 6
For severe/high-risk CRAB infections:
- Combination therapy with two in vitro active antibiotics from: polymyxin, aminoglycoside, tigecycline, or sulbactam combinations 6
Specific combinations to AVOID:
- Polymyxin-meropenem (strong recommendation against) 6
- Polymyxin-rifampin (strong recommendation against) 6
Emerging Therapies
Recent evidence supports sulbactam-durlobactam as showing the greatest mortality reduction for CRAB pulmonary and bloodstream infections 7. This represents a significant advance over traditional polymyxin-based regimens.
Critical Pitfalls to Avoid
Never use aztreonam for CRAB - despite its utility in other gram-negative infections (including metallo-β-lactamase-producing Enterobacterales when combined with ceftazidime-avibactam 8), it has zero activity against Acinetobacter species
Verify susceptibility testing - always confirm in vitro activity before initiating therapy, as CRAB exhibits high rates of pan-resistance 4
Consider renal function - polymyxins require judicious use in renal insufficiency; tigecycline requires caution in hepatic insufficiency 8
Avoid suboptimal monotherapy - combination therapy is suggested for severe infections to prevent treatment failure 6
The 2023 Asian guidelines similarly emphasize that tigecycline-based or polymyxin-based combination therapy should be selected based on patient-specific factors for CRAB pulmonary infections, with neither showing clear superiority 8.